WO2002032414A3 - Ribavirin-pegylated interferon alfa hcv combination therapy - Google Patents

Ribavirin-pegylated interferon alfa hcv combination therapy Download PDF

Info

Publication number
WO2002032414A3
WO2002032414A3 PCT/US2001/032434 US0132434W WO0232414A3 WO 2002032414 A3 WO2002032414 A3 WO 2002032414A3 US 0132434 W US0132434 W US 0132434W WO 0232414 A3 WO0232414 A3 WO 0232414A3
Authority
WO
WIPO (PCT)
Prior art keywords
ribavirin
pegylated interferon
combination therapy
interferon alfa
hcv combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/032434
Other languages
French (fr)
Other versions
WO2002032414A2 (en
Inventor
Janice Albrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01981718A priority Critical patent/EP1326594A2/en
Application filed by Schering Corp filed Critical Schering Corp
Priority to BR0114636-0A priority patent/BR0114636A/en
Priority to AU2002213343A priority patent/AU2002213343A1/en
Priority to JP2002535652A priority patent/JP2004511513A/en
Priority to HU0301444A priority patent/HUP0301444A3/en
Priority to CA002425522A priority patent/CA2425522A1/en
Priority to MXPA03003456A priority patent/MXPA03003456A/en
Priority to HK03105160.0A priority patent/HK1052878A1/en
Publication of WO2002032414A2 publication Critical patent/WO2002032414A2/en
Publication of WO2002032414A3 publication Critical patent/WO2002032414A3/en
Priority to NO20031742A priority patent/NO20031742L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of ribavirin and/or pegylated interferon alfa for the preparation of a pharmaceutical composition for the treatment of chronic hepatitis C infection comprising a therapeutically weight-effective amount of ribavirin and a therapeutically effective amount of pegylated, e.g, pegylated interferon-alfa-2b or -2a, is disclosed.
PCT/US2001/032434 2000-10-18 2001-10-16 Ribavirin-pegylated interferon alfa hcv combination therapy Ceased WO2002032414A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
HK03105160.0A HK1052878A1 (en) 2000-10-18 2001-10-16 Ribavirin-pegylated interferon alfa hcv combination therapy
BR0114636-0A BR0114636A (en) 2000-10-18 2001-10-16 Pegylated interferon-alpha / ribavirin hcv combination therapy
AU2002213343A AU2002213343A1 (en) 2000-10-18 2001-10-16 Ribavirin-pegylated interferon alfa HCV combination therapy
JP2002535652A JP2004511513A (en) 2000-10-18 2001-10-16 Ribavirin-PEGylated interferon alpha HCV combination therapy
HU0301444A HUP0301444A3 (en) 2000-10-18 2001-10-16 The use of ribavirin-pegylated interferon alfa for the preparation of pharmaceutical compositions for the treatment of hcv infection
EP01981718A EP1326594A2 (en) 2000-10-18 2001-10-16 Ribavirin-pegylated interferon alfa hcv combination therapy
MXPA03003456A MXPA03003456A (en) 2000-10-18 2001-10-16 Ribavirin-pegylated interferon alfa hcv combination therapy.
CA002425522A CA2425522A1 (en) 2000-10-18 2001-10-16 Ribavirin-pegylated interferon alfa hcv combination therapy
NO20031742A NO20031742L (en) 2000-10-18 2003-04-15 HCV combination therapy with ribavirin and pegylated interferon alfa

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24155700P 2000-10-18 2000-10-18
US60/241,557 2000-10-18

Publications (2)

Publication Number Publication Date
WO2002032414A2 WO2002032414A2 (en) 2002-04-25
WO2002032414A3 true WO2002032414A3 (en) 2003-04-03

Family

ID=22911172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032434 Ceased WO2002032414A2 (en) 2000-10-18 2001-10-16 Ribavirin-pegylated interferon alfa hcv combination therapy

Country Status (13)

Country Link
US (1) US20020127203A1 (en)
EP (1) EP1326594A2 (en)
JP (1) JP2004511513A (en)
CN (1) CN1516599A (en)
AU (1) AU2002213343A1 (en)
BR (1) BR0114636A (en)
CA (1) CA2425522A1 (en)
HK (1) HK1052878A1 (en)
HU (1) HUP0301444A3 (en)
MX (1) MXPA03003456A (en)
NO (1) NO20031742L (en)
WO (1) WO2002032414A2 (en)
ZA (1) ZA200302525B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
US7192936B2 (en) 2002-06-28 2007-03-20 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7582618B2 (en) 2002-06-28 2009-09-01 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7601820B2 (en) 2004-07-21 2009-10-13 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
US7608597B2 (en) 2000-05-23 2009-10-27 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
CA2470342C (en) * 2001-12-21 2010-05-11 Biopartners Gmbh Ribavirin granulate for producing coated tablets
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
NZ540913A (en) * 2002-12-23 2008-02-29 Idenix Cayman Ltd Process for the production of 3'-nucleoside prodrugs
JP2007501806A (en) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー How to treat a viral infection
CA2554188A1 (en) * 2004-01-23 2005-08-04 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
CA2571675A1 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US8183005B1 (en) 2004-08-11 2012-05-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agents for treating HCV infections
ES2422290T3 (en) 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedure for preparing a synthetic intermediate for the preparation of branched nucleosides
JPWO2007132882A1 (en) * 2006-05-16 2009-09-24 財団法人 東京都医学研究機構 Pharmaceutical composition for treating or preventing HCV infection
BRPI0713278A2 (en) * 2006-07-07 2012-03-06 Meiji Seika Kaisha Ltd prophylactic or therapeutic agent for viral disease
US8793074B2 (en) * 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2368989A4 (en) 2008-11-26 2012-09-26 Chugai Pharmaceutical Co Ltd OLOGORIBONUCLEOTIDE OR PEPTIDE NUCLEIC ACID CAPABLE OF INHIBITING HEPATITIS C VIRUS ACTIVITY
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (en) 2008-12-23 2010-07-27 NUCLEOSID FORFORMIDATES
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
WO2011001897A1 (en) * 2009-06-30 2011-01-06 明治製菓株式会社 Medicinal agent and method for treatment of intractable chronic hepatitis c
WO2011002584A1 (en) * 2009-07-02 2011-01-06 The University Of Iowa Research Foundation Treatment of hepatitis c virus infections
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
DE202012012955U1 (en) 2011-10-21 2014-07-14 Abbvie Inc. A combination of at least two direct-acting antiviral agents (DAAs) for use in the treatment of HCV
CN104704129A (en) 2012-07-24 2015-06-10 药品循环公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (BTK)
TW201427664A (en) 2012-11-02 2014-07-16 Pharmacyclics Inc TEC family kinase inhibitor adjuvant therapy
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
PT3038601T (en) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016204A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
EP0956861A1 (en) * 1998-05-15 1999-11-17 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
WO2000037110A2 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6635646B1 (en) * 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US6924270B2 (en) * 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
WO2003024461A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016204A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
EP0956861A1 (en) * 1998-05-15 1999-11-17 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
WO2000037110A2 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A.ERHARDT E.A.: "Therapie und Diagnostik der chronischen Hepatitis C", VERDAUUNGSKRANKHEITEN, vol. 18, no. 3, 2000, pages 123 - 133, XP008011268 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608597B2 (en) 2000-05-23 2009-10-27 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
US7635689B2 (en) 2002-06-28 2009-12-22 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7547704B2 (en) 2002-06-28 2009-06-16 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7582618B2 (en) 2002-06-28 2009-09-01 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7192936B2 (en) 2002-06-28 2007-03-20 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7365057B2 (en) 2002-06-28 2008-04-29 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flavivridae infections
US7384924B2 (en) 2002-06-28 2008-06-10 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7625875B2 (en) 2002-06-28 2009-12-01 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
US10287311B2 (en) 2003-05-30 2019-05-14 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7601820B2 (en) 2004-07-21 2009-10-13 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9585906B2 (en) 2007-03-30 2017-03-07 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9394331B2 (en) 2010-11-30 2016-07-19 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Also Published As

Publication number Publication date
CN1516599A (en) 2004-07-28
ZA200302525B (en) 2004-07-21
MXPA03003456A (en) 2003-07-14
EP1326594A2 (en) 2003-07-16
NO20031742L (en) 2003-06-17
HK1052878A1 (en) 2003-10-03
JP2004511513A (en) 2004-04-15
BR0114636A (en) 2004-02-10
AU2002213343A1 (en) 2002-04-29
CA2425522A1 (en) 2002-04-25
HUP0301444A2 (en) 2003-11-28
WO2002032414A2 (en) 2002-04-25
HUP0301444A3 (en) 2007-05-29
NO20031742D0 (en) 2003-04-15
US20020127203A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
WO2002032414A3 (en) Ribavirin-pegylated interferon alfa hcv combination therapy
AU2001255495A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
IL207259A (en) Use of compositions comprising ribavirin and interferon alpha for the preparation of medications for antiviral treatment of naive patients having chronic hepatitis c infection
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
AU1197600A (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
CA2245938A1 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
CA2413163A1 (en) 3'-prodrugs of 2'-deoxy-.beta.-l-nucleosides
CA2288038A1 (en) Polyethylene glycol-interferon alpha conjugates for therapy of infection
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
SI1404347T1 (en) 4'-substituded nucleosides for the treatment of diseases mediated by the hepatitis c virus
WO2001066132A3 (en) Hiv immune adjuvant therapy
AR022116A1 (en) COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
WO2000018417A3 (en) Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine
WO2004094991A3 (en) Treatment or prevention of respiratory viral infections with alpha thymosin peptides
WO2000051631A3 (en) Pegylated alpha interferon for hiv therapy
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO2002089828A3 (en) Interferons in the treatment of ischemia
WO2004067024A3 (en) Hcv combination therapy
AU2453697A (en) Use of photopheresis in the treatment of chronic infection by hepatitis c virus
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
HK1035906A (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
WO2000075354A3 (en) Adenoviral vectors encoding interferon and their use in gene therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 524802

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002213343

Country of ref document: AU

Ref document number: 1-2003-500157

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2001981718

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003/02525

Country of ref document: ZA

Ref document number: 200302525

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002535652

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2425522

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/A/2003/003456

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 018176038

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001981718

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001981718

Country of ref document: EP